Stock Events

Stock Events

Prelude Therapeutics 

$5.46
24
+$0.21+4% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
5.52
Day Low
5.19
52W High
6.83
52W Low
0.981
Volume
400,284
Avg. Volume
489,301
Mkt Cap
435.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.47
-0.27
-0.08
0.11
Expected EPS
0.11
Actual EPS
N/A

Financials

-819.59%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
12.14MRevenue
-99.5MNet Income

Analyst Ratings

7.67Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRLD. It's not an investment recommendation.
Microsoft
6
MSFT
Amazon
6
AMZN
NVIDIA
6
NVDA
Vanguard S&P 500
6
VOO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to cancer treatment, making it a competitor in the oncology space.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad oncology portfolio, competing across multiple areas including those targeted by Prelude.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in oncology and cell therapy, areas where Prelude is aiming to make advancements.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse oncology pipeline that includes cell therapy and biologics, competing with Prelude's cancer research efforts.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad portfolio in cancer therapeutics, directly competing with Prelude's focus on innovative cancer treatments.
Merck
MRK
Mkt Cap366B
Merck is known for its cancer drug Keytruda among others, making it a strong competitor in the oncology market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a wide range of cancer treatments and is heavily invested in oncology research, competing with Prelude's therapeutic developments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing monoclonal antibodies for cancer, directly competing with Prelude's approach to cancer therapy.

About

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Show more...
CEO
Krishna Vaddi
Employees
79
Country
United States
ISIN
US74065P1012

Listings

BOATS
BOATS
PRLD.BOATS
XNAS
US
PRLD

0 Comments

Share your thoughts

FAQ

What is Prelude Therapeutics stock price today?▼
The current price of PRLD is $5.46 USD — it has increased by +4% in the past 24 hours. Watch Prelude Therapeutics stock price performance more closely on the chart.
What is Prelude Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Prelude Therapeutics stocks are traded under the ticker PRLD.
Is Prelude Therapeutics stock price growing?▼
PRLD stock has fallen by -0.18% compared to the previous week, the month change is a +20.8% rise, over the last year Prelude Therapeutics has showed a +378.95% increase.
What is Prelude Therapeutics market cap?▼
Today Prelude Therapeutics has the market capitalization of 435.73M
When is the next Prelude Therapeutics earnings date?▼
Prelude Therapeutics is going to release the next earnings report on November 05, 2026.
What were Prelude Therapeutics earnings last quarter?▼
PRLD earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.2 USD resulting in a +28.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prelude Therapeutics revenue for the last year?▼
Prelude Therapeutics revenue for the last year amounts to 12.14M USD.
What is Prelude Therapeutics net income for the last year?▼
PRLD net income for the last year is -99.5M USD.
How many employees does Prelude Therapeutics have?▼
As of September 04, 2026, the company has 79 employees.
In which sector is Prelude Therapeutics located?▼
Prelude Therapeutics operates in the Health & Wellness sector.
When did Prelude Therapeutics complete a stock split?▼
Prelude Therapeutics has not had any recent stock splits.
Where is Prelude Therapeutics headquartered?▼
Prelude Therapeutics is headquartered in WILMINGTON, United States.